サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566754

ヒトインスリン市場：製品タイプ別、適応症別、インスリンタイプ別、流通チャネル別：世界の機会分析と産業予測、2024～2033年

Human Insulin Market By Product Type, By Indication By Type of Insulin By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 245 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ヒトインスリン市場：製品タイプ別、適応症別、インスリンタイプ別、流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 245 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒトインスリン市場

ヒトインスリン市場は、2023年に171億米ドルと評価され、2024～2033年にかけてCAGR 3.4%で成長し、2033年には240億米ドルに達すると予測されています。

ヒトインスリンは天然ペプチドホルモンの合成模倣品であり、実験室で大腸菌内で合成されます。短時間作用型の通常型と、神経プロタミンヘーゲドンインスリンとして知られる中間型があります。ヒトインスリンは、体内で自然に産生されるインスリンの代わりとなり、血液中のグルコースレベルを調節します。

ヒトインスリン市場の主要促進要因は、世界の糖尿病有病率の増加です。また、ヒトインスリンは、その高い有効性とアレルギー反応の最小限のリスクにより、動物性インスリンと比較して、患者や開業医からの需要が急増しています。ヒトインスリン市場の最新動向は、同等の有効性と高い費用対効果により、患者がバイオシミラー製品に傾倒していることです。

しかし、経口薬やGLP-1受容体作動薬を含む非インスリン注射薬などの他の代替品の存在は、ヒトインスリンに大きな競合を提供しています。さらに、ヒトインスリンの市場への導入は、前臨床段階、臨床試験、市販後の安全性モニタリングなど、さまざまな段階での規制当局の承認手続きに時間がかかるため、複雑で時間のかかるプロセスとなっています。このため、タンパク質の入手が遅れ、市場の開拓が制限されます。これとは逆に、AIや機械学習などのデータ主導型アプローチの統合は、生産パラメーターの最適化や製品収率の予測によって生産効率を加速させることが期待されています。

セグメント別レビュー

ヒトインスリン市場は、製品タイプ、適応症、インスリンタイプ、流通チャネル、地域に区分されます。製品タイプ別では、市場はペン、シリンジ、その他に分けられます。適応症別では、1型糖尿病、2型糖尿病、妊娠糖尿病に分類されます。インスリンタイプにより、速効型インスリン、短時間作用型インスリン、中間作用型インスリン、その他に分類されます。流通チャネルでは、病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダーに分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

製品タイプ別では、2023年にはペンセグメントが市場を独占しました。

適応症別では、1型糖尿病セグメントが2023年の市場で高い地位を獲得しました。

インスリンタイプ別では、速効型インスリンセグメントが2023年に高い市場シェアを獲得しました。

流通チャネル別では、ドラッグストア・小売薬局セグメントが2023年に最も高いシェアを獲得しました。

地域別では、北米が2023年に最も高い収益を上げました。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 製品タイプ別ヒトインスリン市場

  • 市場概要
  • ペン
  • 注射器
  • その他

第5章 ヒトインスリン市場：適応症別

  • 市場概要
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第6章 ヒトインスリン市場：インスリンタイプ別

  • 市場概要
  • 速効型インスリン
  • 短時間作用型インスリン
  • 中間作用型インスリン
  • その他

第7章 ヒトインスリン市場：流通チャネル別

  • 市場概要
  • 病院薬局
  • ドラッグストアと小売薬局
  • オンラインプロバイダー

第8章 ヒトインスリン市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のヒトインスリン市場
    • カナダのヒトインスリン市場
    • メキシコのヒトインスリン市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのヒトインスリン市場
    • フランスのヒトインスリン市場
    • 英国のヒトインスリン市場
    • イタリアのヒトインスリン市場
    • スペインのヒトインスリン市場
    • その他の欧州のヒトインスリン市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のヒトインスリン市場
    • 中国のヒトインスリン市場
    • インドのヒトインスリン市場
    • オーストラリアのヒトインスリン市場
    • 韓国のヒトインスリン市場
    • その他のアジア太平洋のヒトインスリン市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのヒトインスリン市場
    • サウジアラビアのヒトインスリン市場
    • 南アフリカのヒトインスリン市場
    • その他のラテンアメリカ・中東・アフリカのヒトインスリン市場

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第10章 企業プロファイル

  • Eli Lilly And Company
  • Sanofi
  • Novo Nordisk A/S
  • Pfizer
  • Biocon
  • Wockhardt
  • MannKind Corporation
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Medtronic
  • Lupin
目次
Product Code: A00321

Human Insulin Market

The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.

Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.

A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.

However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.

Segment Review

The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the pens segment dominated the market in 2023.

As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.

Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.

According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Pens
  • Syringes
  • Others

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Type Of Insulin

  • Rapid-acting insulin
  • Short-acting insulin
  • Intermediate-acting insulin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Pfizer
    • Biocon
    • Wockhardt
    • MannKind Corporation
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Medtronic
    • Lupin

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Pens
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Syringes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Type 1 Diabetes
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Type 2 Diabetes
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Gestational Diabetes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Type of Insulin
  • 6.2. Rapid-acting Insulin
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Short-acting Insulin
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Intermediate-acting Insulin
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: HUMAN INSULIN MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Product Type
    • 8.2.3. Market Size and Forecast, By Indication
    • 8.2.4. Market Size and Forecast, By Type of Insulin
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Human Insulin Market
      • 8.2.7.1. Market Size and Forecast, By Product Type
      • 8.2.7.2. Market Size and Forecast, By Indication
      • 8.2.7.3. Market Size and Forecast, By Type of Insulin
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Human Insulin Market
      • 8.2.8.1. Market Size and Forecast, By Product Type
      • 8.2.8.2. Market Size and Forecast, By Indication
      • 8.2.8.3. Market Size and Forecast, By Type of Insulin
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Human Insulin Market
      • 8.2.9.1. Market Size and Forecast, By Product Type
      • 8.2.9.2. Market Size and Forecast, By Indication
      • 8.2.9.3. Market Size and Forecast, By Type of Insulin
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Product Type
    • 8.3.3. Market Size and Forecast, By Indication
    • 8.3.4. Market Size and Forecast, By Type of Insulin
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Human Insulin Market
      • 8.3.7.1. Market Size and Forecast, By Product Type
      • 8.3.7.2. Market Size and Forecast, By Indication
      • 8.3.7.3. Market Size and Forecast, By Type of Insulin
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Human Insulin Market
      • 8.3.8.1. Market Size and Forecast, By Product Type
      • 8.3.8.2. Market Size and Forecast, By Indication
      • 8.3.8.3. Market Size and Forecast, By Type of Insulin
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Human Insulin Market
      • 8.3.9.1. Market Size and Forecast, By Product Type
      • 8.3.9.2. Market Size and Forecast, By Indication
      • 8.3.9.3. Market Size and Forecast, By Type of Insulin
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Human Insulin Market
      • 8.3.10.1. Market Size and Forecast, By Product Type
      • 8.3.10.2. Market Size and Forecast, By Indication
      • 8.3.10.3. Market Size and Forecast, By Type of Insulin
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Human Insulin Market
      • 8.3.11.1. Market Size and Forecast, By Product Type
      • 8.3.11.2. Market Size and Forecast, By Indication
      • 8.3.11.3. Market Size and Forecast, By Type of Insulin
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Human Insulin Market
      • 8.3.12.1. Market Size and Forecast, By Product Type
      • 8.3.12.2. Market Size and Forecast, By Indication
      • 8.3.12.3. Market Size and Forecast, By Type of Insulin
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Product Type
    • 8.4.3. Market Size and Forecast, By Indication
    • 8.4.4. Market Size and Forecast, By Type of Insulin
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Human Insulin Market
      • 8.4.7.1. Market Size and Forecast, By Product Type
      • 8.4.7.2. Market Size and Forecast, By Indication
      • 8.4.7.3. Market Size and Forecast, By Type of Insulin
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Human Insulin Market
      • 8.4.8.1. Market Size and Forecast, By Product Type
      • 8.4.8.2. Market Size and Forecast, By Indication
      • 8.4.8.3. Market Size and Forecast, By Type of Insulin
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Human Insulin Market
      • 8.4.9.1. Market Size and Forecast, By Product Type
      • 8.4.9.2. Market Size and Forecast, By Indication
      • 8.4.9.3. Market Size and Forecast, By Type of Insulin
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Human Insulin Market
      • 8.4.10.1. Market Size and Forecast, By Product Type
      • 8.4.10.2. Market Size and Forecast, By Indication
      • 8.4.10.3. Market Size and Forecast, By Type of Insulin
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Human Insulin Market
      • 8.4.11.1. Market Size and Forecast, By Product Type
      • 8.4.11.2. Market Size and Forecast, By Indication
      • 8.4.11.3. Market Size and Forecast, By Type of Insulin
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Human Insulin Market
      • 8.4.12.1. Market Size and Forecast, By Product Type
      • 8.4.12.2. Market Size and Forecast, By Indication
      • 8.4.12.3. Market Size and Forecast, By Type of Insulin
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Product Type
    • 8.5.3. Market Size and Forecast, By Indication
    • 8.5.4. Market Size and Forecast, By Type of Insulin
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Human Insulin Market
      • 8.5.7.1. Market Size and Forecast, By Product Type
      • 8.5.7.2. Market Size and Forecast, By Indication
      • 8.5.7.3. Market Size and Forecast, By Type of Insulin
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Human Insulin Market
      • 8.5.8.1. Market Size and Forecast, By Product Type
      • 8.5.8.2. Market Size and Forecast, By Indication
      • 8.5.8.3. Market Size and Forecast, By Type of Insulin
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Human Insulin Market
      • 8.5.9.1. Market Size and Forecast, By Product Type
      • 8.5.9.2. Market Size and Forecast, By Indication
      • 8.5.9.3. Market Size and Forecast, By Type of Insulin
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Human Insulin Market
      • 8.5.10.1. Market Size and Forecast, By Product Type
      • 8.5.10.2. Market Size and Forecast, By Indication
      • 8.5.10.3. Market Size and Forecast, By Type of Insulin
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Eli Lilly And Company
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Sanofi
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Pfizer
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Biocon
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Wockhardt
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. MannKind Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Medtronic
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Lupin
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments